Adam Rosenthal, Star Therapeutics CEO

A new start­up sets course against a con­stel­la­tion of rare dis­eases with a first shot re­pur­pos­ing the SIRP path­way

De­spite some big ad­vances in re­cent years, rare dis­ease re­mains a most­ly un­chart­ed wilder­ness with many pa­tients left un­der­served. A start­up with galac­tic am­bi­tions now hopes to bust open a wide range of such dis­eases, and its first ef­fort has eyes on a fa­mil­iar can­cer tar­get.

Star Ther­a­peu­tics emerged from stealth Wednes­day fo­cused on crack­ing the code in a con­stel­la­tion of rare dis­eases with a first spin­out com­pa­ny tar­get­ing the SIRP path­way for im­munol­o­gy and can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.